Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
MRI scanner in a dimly lit hospital imaging room with a technician

Oct 20, 2026

Subtle Medical Adds Distribution Partners in the UK and Italy to Support European Growth

Subtle Medical is expanding its European presence through new distribution agreements with AMG Medtech in the UK and Medical Horizons in Italy, aimed at addressing the rising demand for MRI and PET imaging solutions.The partnerships will facilitate the distribution of SubtleHD™(MR) and SubtleHD™(PET), AI-driven technologies designed to enhance the speed and quality of imaging exams. With over 1,500 scanners already utilizing Subtle Medical's software globally, the company is responding to signif
Illustration of RNA fusion

Oct 20, 2026

New Pipeline Reveals RNA Fusions Formed During Inflammation, Opens New Frontier in Biology

Recent research has unveiled a groundbreaking mechanism by which immune cells generate novel messenger RNAs during inflammatory responses, potentially redefining our understanding of gene functionality.Scientists have discovered that during inflammation, immune cells can create chimeric mRNAs by fusing segments from disparate genes, a process previously thought to result mainly from DNA damage. This study, led by researchers at Harvard Medical School, demonstrates that these fused RNAs play a si
Press release cover image

Oct 20, 2026

Press release

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyondGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis an
A minimalist illustration of a patient and a magnifying glass representing clinical trial recruitment.

Oct 20, 2026

AstraZeneca taps Oracle to help improve recruitment for clinical trials

AstraZeneca collaborates with Oracle to enhance clinical trial recruitment efficiency, addressing a long-standing challenge in drug development.The partnership, established through a non-binding agreement, aims to leverage advanced applications and AI to streamline the clinical trial process. This collaboration is particularly focused on improving the early identification of eligible patients across various disease areas, including oncology, rare diseases, cardiovascular, renal, metabolic, respi
Press release cover image

Oct 20, 2026

Press release

Jupiter Endovascular Announces Publication of SPIRARE II Pivotal Trial Results Showing Vertex Thrombectomy System Normalized Hemodynamics in 50% of Pulmonary Embolism Patients

Peer-reviewed Data Published in EuroIntervention Also Demonstrated Vertex System Achieved Rapid Afterload Relief – or Reduction in Heart Strain – and Symptom ImprovementMENLO PARK, Calif.--(BUSINESS WIRE)--#EuroIntervention--Jupiter Endovascular, Inc.today announced publication of full results from its SPIRARE II pivotal trial evaluating the Vertex™ Thrombectomy System in patients with acute, intermediate-risk pulmonary embolism (PE), in the latest issue of EuroIntervention. The trial met all pr
Press release cover image

Oct 20, 2026

Press release

Kane to Showcase revyve® at Wounds Canada National Hybrid Conference

Engaging Canadian wound-care professionals, presenting data and discussing biofilm management in clinical practice WINNIPEG, Manitoba, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will attend the Wounds Canada National Hybrid Conference, taking place October 22-24, 2026, in Niagara Falls, Ontario.
Press release cover image

Oct 20, 2026

Press release

Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam

Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion's EBV immunotherapeutic programROCKVILLE, Md.--(BUSINESS WIRE)--Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers, today announced that Chief Executive Officer Dr. Gregory Glenn will take part in two sessions at the 27th World Vaccine Congress Europe, held October 19 to 21 at the RAI Conven
Press release cover image

Oct 20, 2026

Press release

Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

Data featured as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear MedicineFirst-in-human imaging performed in 10 patients with non-small cell lung cancer showed no tracer-related serious adverse events, high lesion contrast and tumor uptake that rose with c-MET expression, demonstrating high theranostic potentialGlobal regulatory clearances support advancing [225Ac]Ac-FL-261 into Phase 1 clinical trialsLONDON, Oct. 19, 2026 /PRNewswire/ -- Full-Lif
Press release cover image

Oct 20, 2026

Press release

Baylor Genetics to Highlight Clinical and Diagnostic Utility of Genome Sequencing at the 2026 American Society of Human Genetics Annual Meeting

HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it will share new genome sequencing data in two platform presentations and a poster presentation at the 2026 American Society of Human Genetics (ASHG) Annual Meeting in Montréal, Québec, Canada from Oct. 20-24, 2026. “The data we’re sharing at this year’s ASHG meeting reinforces the role of genome seque
Press release cover image

Oct 20, 2026

Press release

Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026

PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026, held October 23–27 in Madrid, Spain.Riboscience to Present First Overall Survival Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 at ESMO 2026ESMO 2026 Poster Presentation Deta
A glass vial with a colorful drug compound on a lab bench, surrounded by laboratory equipment.

Oct 20, 2026

OpenAI acquires Orchestra Bio

OpenAI has expanded its capabilities in drug development by acquiring Orchestra Bio, a platform designed to streamline the complex processes involved in biopharma projects.This acquisition merges Orchestra's expertise with OpenAI's Rosalind, which provides advanced AI tools for life sciences research. The collaboration aims to enhance the efficiency of drug development, which typically takes 10 to 15 years, by integrating AI into various workflows that involve both internal teams and external pa
A blood sample in a lab setting

Oct 19, 2026

Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters

A groundbreaking collaboration between IMU Biosciences and the UK Biobank aims to create an extensive and detailed map of the human immune system, leveraging advanced technologies and AI methodologies.The initiative seeks to enhance the UK Biobank's existing dataset by adding high-resolution immune data, generating over 100 million immune data points from tens of thousands of samples. This will result in the most comprehensive immune dataset to date. The project utilizes IMU’s HD Immunology plat